NGLFINE Stock Overview
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NGL Fine-Chem Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,525.10 |
| 52 Week High | ₹2,823.90 |
| 52 Week Low | ₹1,400.00 |
| Beta | 1.01 |
| 1 Month Change | 20.59% |
| 3 Month Change | 29.10% |
| 1 Year Change | 69.50% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 35.11% |
Recent News & Updates
Shareholder Returns
| NGLFINE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -2.5% | 1.6% | 2.1% |
| 1Y | 69.5% | 57.6% | 45.9% |
Return vs Industry: NGLFINE exceeded the Indian Pharmaceuticals industry which returned 56.7% over the past year.
Return vs Market: NGLFINE exceeded the Indian Market which returned 45% over the past year.
Price Volatility
| NGLFINE volatility | |
|---|---|
| NGLFINE Average Weekly Movement | 7.5% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in IN Market | 10.0% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: NGLFINE's share price has been volatile over the past 3 months.
Volatility Over Time: NGLFINE's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 396 | Rahul Nachane | www.nglfinechem.com |
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for use in veterinary and human health worldwide. It offers active pharmaceutical ingredients, such as diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, xylazine hydrochloride, and marbofloxacin for animal health applications; and nitazoxanide and atovaquone for human health applications. The company provides various intermediate products and specialty chemicals; and finished dosage forms in granules and tablets.
NGL Fine-Chem Limited Fundamentals Summary
| NGLFINE fundamental statistics | |
|---|---|
| Market cap | ₹15.65b |
| Earnings (TTM) | ₹380.04m |
| Revenue (TTM) | ₹3.17b |
41.2x
P/E Ratio4.9x
P/S RatioIs NGLFINE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NGLFINE income statement (TTM) | |
|---|---|
| Revenue | ₹3.17b |
| Cost of Revenue | ₹1.55b |
| Gross Profit | ₹1.62b |
| Other Expenses | ₹1.24b |
| Earnings | ₹380.04m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 61.51 |
| Gross Margin | 51.24% |
| Net Profit Margin | 11.99% |
| Debt/Equity Ratio | 11.3% |
How did NGLFINE perform over the long term?
See historical performance and comparison